A judge has signed off on a $42.5 million settlement of a class action against Cash Converters, brought on behalf of consumers that look out personal loans, in a move that will see the plaintiffs firm behind the case pocket $12.4 million.
The Kingdom of Spain is keeping up its fight against the enforcement of two arbitration awards putting it on the hook for paying two investment companies $375 million.
Generic drug maker Juno Pharmaceuticals has agreed to stopped planned sales of its cheap version of Millennium Pharmaceuticals anti-cancer medication Velcade in Australia as part of a settlement of its lawsuit alleging two patents covering the drug were invalid.
A judge has criticised the parties in a land sale dispute over Sydney’s Parklea Markets for failing to make progress to bring the case to a close, almost three months after a $4.25 million judgment was awarded to a company owned by local retail personality Con Constantine.
Australian swimwear retailer Tigerlily has filed for voluntary administration, citing unfavourable conditions for retailers as the coronavirus pandemic shutters all but non-essential services in major states.
The Australian Securities and Investments Commission will continue its enforcement activities amid the spread of the coronavirus but will prioritise cracking down on behaviour that threatens “immediate consumer harm”.
A dispute over approximately $466,000 in unpaid legal costs has been sent to the Victorian Supreme Court after DLA Piper admitted it breached its disclosure obligations to a client in a patent case over a laser safety system.
For the lawyers conducting the committal hearings in the criminal cartel case over ANZ’s $2.5 billion equity raising, the Sydney Downing Centre courtroom was already too close for comfort.
Fairfax Media has failed in its appeal of a judgment that found the publisher defamed Chinese-Australian businessman Dr Chau Chak Wing in a Sydney Morning Herald article that linked him to an international bribery scandal.
AFT Pharmaceuticals has lost its challenge to a ruling that ads claiming its painkiller Maxigesic is more effective than Nuremol were misleading and deceptive, with the Full Federal Court saying the primary judge did not err in finding the ads lacked an adequate scientific basis.